Pfizer Inc.’s next-generation treatment for breast cancer posted mixed results in a final-stage study, a potential setback ...

An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients ...

Senators ask if contracts between drugmakers and telehealth companies violate the federal anti-kickback statute.

Senators question Pfizer's partnership with UpScriptHealth, citing potential anti-kickback concerns and risks of increased ...

Pfizer's Covid-19 vaccine is considered by healthcare authorities to be safe and effective, with data gathered from billions ...

However, its potential is seen as being tied to the ability of the drug to target the broader population of ESR1 'wild-type' patients While Pfizer trumpeted the result as a "clinically meaningful ...

The top 10 projected best-selling medications in 2026, including GLP-1 drugs and AbbVie's Skyrizi, have expected global sales reaching up to $31 billiion.

In their own responses to the senators’ inquiries last fall, both Pfizer and Lilly emphasized the independence of their ...

The Maryland Senate voted to allow a state board to extend its mandate for lowering prescription drug costs to all residents.

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...

Vepdegestrant did not improve progression-free survival broadly but saw improvements in one specific patient cohort. Arvinas’ ...

Discover the strengths & weaknesses of healthcare giants Johnson & Johnson and Pfizer. Find out which stock is more promising ...